Evidence map›Paper›PMID 26681767›Full record

ArticleNeuro-oncology2016

Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis.

Zhou Xu, Xingruo Zeng, Jiawei Xu, Derek Xu, Jingxia Li, Honglei Jin, Guosong Jiang, Xiaosi Han, Chuanshu Huang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. RNAFrontiers in oncology · 2021
    Review
  13. The Risks of miRNA Therapeutics: In a Drug Target Perspective.Drug design, development and therapy · 2021
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. circPTN sponges miR-145-5p/miR-330-5p to promote proliferation and stemness in glioma.Journal of experimental & clinical cancer research : CR · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Zhou XuNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York (Z.X., X.Z., J.X., D.X., J.L., H.J., G.J., C.H.); Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China (Z.X.); Division of Neuro-Oncology, Department of Neurology, University of Alabama, Birmingham, Alabama (X.H.).
Xingruo ZengNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York (Z.X., X.Z., J.X., D.X., J.L., H.J., G.J., C.H.); Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China (Z.X.); Division of Neuro-Oncology, Department of Neurology, University of Alabama, Birmingham, Alabama (X.H.).
Jiawei XuNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York (Z.X., X.Z., J.X., D.X., J.L., H.J., G.J., C.H.); Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China (Z.X.); Division of Neuro-Oncology, Department of Neurology, University of Alabama, Birmingham, Alabama (X.H.).
Derek XuNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York (Z.X., X.Z., J.X., D.X., J.L., H.J., G.J., C.H.); Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China (Z.X.); Division of Neuro-Oncology, Department of Neurology, University of Alabama, Birmingham, Alabama (X.H.).
Jingxia LiNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York (Z.X., X.Z., J.X., D.X., J.L., H.J., G.J., C.H.); Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China (Z.X.); Division of Neuro-Oncology, Department of Neurology, University of Alabama, Birmingham, Alabama (X.H.).
Honglei JinNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York (Z.X., X.Z., J.X., D.X., J.L., H.J., G.J., C.H.); Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China (Z.X.); Division of Neuro-Oncology, Department of Neurology, University of Alabama, Birmingham, Alabama (X.H.).
Guosong JiangNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York (Z.X., X.Z., J.X., D.X., J.L., H.J., G.J., C.H.); Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China (Z.X.); Division of Neuro-Oncology, Department of Neurology, University of Alabama, Birmingham, Alabama (X.H.).
Xiaosi HanNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York (Z.X., X.Z., J.X., D.X., J.L., H.J., G.J., C.H.); Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China (Z.X.); Division of Neuro-Oncology, Department of Neurology, University of Alabama, Birmingham, Alabama (X.H.).
Chuanshu HuangNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York (Z.X., X.Z., J.X., D.X., J.L., H.J., G.J., C.H.); Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China (Z.X.); Division of Neuro-Oncology, Department of Neurology, University of Alabama, Birmingham, Alabama (X.H.).
New York University · USRenmin Hospital of Wuhan University · CNUniversity of Alabama at Birmingham · USWuhan University · CN

Funding

Reagent/Service CoreP01CA165980 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI TANG, ERIC MOON-SHONG M. · 2013 to 2023
$13.5M
Molecular Mechanisms of Nickel-Induced TumorigenicityR01CA112557 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUANG, CHUANSHU · 2004 to 2016
$2.9M
Mechanisms underlying therapeutic effect of a new compound Isorhapontigenin (ISO)R01CA177665 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUANG, CHUANSHU · 2013 to 2018
$1.7M
Targeting PRMT5 in Cancer Initiating Cells as a New Therapy for GlioblastomaR01NS095626 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HAN, XIAOSI · 2015 to 2019
$1.6M
NCI NIH HHS P01 CA165980NCI NIH HHS R01 CA112557NCI NIH HHS R01 CA177665NINDS NIH HHS R01 NS095626
6 · The paper itself

Abstract

backgroundGlioblastoma (GBM) is the most common malignant brain tumor, and glioma stem cells (GSCs) are considered a major source of treatment resistance for glioblastoma. Identifying new compounds that inhibit the growth of GSCs and understanding their underlying molecular mechanisms are therefore important for developing novel therapy for GBM.

methodsWe investigated the potential inhibitory effect of isorhapontigenin (ISO), an anticancer compound identified in our recent investigations, on anchorage-independent growth of patient-derived glioblastoma spheres (PDGS) and its mechanism of action.

resultsISO treatment resulted in significant anchorage-independent growth inhibition, accompanied with cell cycle G0-G1 arrest and cyclin D1 protein downregulation in PDGS. Further studies established that cyclin D1 was downregulated by ISO at transcription levels in a SOX2-dependent manner. In addition, ISO attenuated SOX2 expression by specific induction of miR-145, which in turn suppressed 3'UTR activity of SOX2 mRNA without affecting its mRNA stability. Moreover, ectopic expression of exogenous SOX2 rendered D456 cells resistant to induction of cell cycle G0-G1 arrest and anchorage-independent growth inhibition upon ISO treatment, whereas inhibition of miR-145 resulted in D456 cells resistant to ISO inhibition of SOX2 and cyclin D1 expression. In addition, overexpression of miR-145 mimicked ISO treatment in D456 cells.

conclusionsISO induces miR-145 expression, which binds to the SOX2 mRNA 3'UTR region and inhibits SOX2 protein translation. Inhibition of SOX2 leads to cyclin D1 downregulation and PDGS anchorage-independent growth inhibition. The elucidation of the miR-145/SOX2/cyclin D1 axis in PDGS provides a significant insight into understanding the anti-GBM effect of ISO compound.

Indexed as

Brain NeoplasmsCell Line, TumorCell ProliferationCyclin D1Gene Expression Regulation, NeoplasticGlioblastomaHumansMicroRNAsSOXB1 Transcription FactorsStilbenesCCND1 protein, humanCyclin D1isorhapontigeninMicroRNAsMIRN145 microRNA, humanSOX2 protein, humanSOXB1 Transcription FactorsStilbenescell cyclecyclin D1glioblastoma sphereisorhapontigeninmiR-145

Identifiers

PMID26681767
PMCPMC4864260
OpenAlexW2298558468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.